Chest
-
Randomized Controlled Trial Multicenter Study
Results of a phase 2b trial with GB001, a DP2 antagonist, in moderate-to-severe eosinophilic asthma.
Prostaglandin D2 receptor 2 (DP2) antagonists inhibit prostaglandin D2-induced effects, including recruitment and activation of cells driving asthma pathogenesis. However, challenges identifying target population and end points persist. ⋯ gov.